- Don Kufe, MD, Professor of Medicine, Harvard Medical School and
Charles Lilly, CA, join Bradmer Board -
TORONTO, Sept. 30 /CNW/ - Bradmer Pharmaceuticals Inc. (TSX: BMR), a
biopharmaceutical company dedicated to the development and commercialization
of cancer therapies, today announced changes to its Board of Directors.
Dr. Ed Miller, the Dean and Chief Executive Officer of Johns Hopkins
University School of Medicine, notified Bradmer that since the Company has
entered into discussions with Johns Hopkins as a site for its Phase III
Neuradiab(TM) trial, he is required to remove himself from the Board to avoid
any potential conflict of interest. Dr. Miller will be replaced on the Board
by Dr. Donald Kufe, Professor of Medicine, Harvard Medical School and
Director, Experimental Therapeutics Program, Dana-Farber/Harvard Cancer
"While we are sorry to lose Dr. Miller as a member of the Board, it is a
sign of our progress that numerous leading medical institutions are agreeing
to participate in the Neuradiab trial. These institutions have rigorous
conflict of interest policies which Bradmer will scrupulously follow,"
commented Mark C. Rogers, MD, Chairman of Bradmer.
Donald Kufe, MD, is Leader of the Translational Pharmacology and Early
Therapeutics Trials Program at the Dana-Farber/Harvard Cancer Center and
Professor of Medicine at Harvard Medical School. Dr. Kufe has worked at the
Dana-Farber Cancer Institute on the molecular biology of human cancer and the
development of anti-cancer agents for nearly 30 years. The focus of his
research has been on the role of the MUC1 oncoprotein in the development of
human cancers. Dr. Kufe has served as the Deputy Director of the Dana-Farber
Cancer Center and as Leader of the Experimental Therapeutics Program. Dr. Kufe
has over 500 publications and is lead editor of the widely recognized
textbook, Cancer Medicine. Dr. Kufe holds numerous patents related to
anti-cancer treatment and is an advisor to multiple pharmaceutical companies.
Dr. Kufe has founded companies that include GenVec (Nasdaq), Convergence
Pharmaceuticals (acquired by ILEX Oncology and Genzyme), Bradmer
Pharmaceuticals (TSX) and Genus Oncology.
"I am pleased that Dr. Kufe has joined the Board since he is among the
top clinical scientists in the field who will bring depth to our multiple
therapeutic applications with Neuradiab," said Alan M. Ezrin, Ph.D., President
and Chief Executive Officer of Bradmer. "The ability of Dr. Kufe to
participate directly with the Board in discussions on clinical oncology and
the competitive advantages of Neuradiab will greatly enhance the strategic
discussions at the Board level."
Charles James Lilly, CA, of Sudbury, Ontario has also been appointed to
the Company's Board. Mr. Lilly is replacing Peter W. Roberts, FCA, CPA
(Illinois), ICD.D, who has decided to step down after serving as a Director
since the Company's inception. Mr. Lilly who lives in Ontario, Canada will be
able to actively participate in the expanding financial interactions and
governance aspects of the board related activities associated with the
increasing corporate development activities related to Neuradiab. In addition,
Mr. Lilly will also serve as Chair of the Audit Committee.
"Charles brings a great deal of accounting acumen to Bradmer. His
experience and knowledge as a long-time senior partner with a public
accounting firm is a great addition to our Board that already has a strong
base of clinical and business experience," said Dr. Rogers. "Peter Roberts has
been a most valuable person to Bradmer since its formation and we are sorry to
have him leave. Nevertheless, with Peter in Vancouver and the accelerating
pace of business decisions taking place in Toronto, it is advantageous to have
the ability to have a locally available person of Chuck's experience to help
us evaluate many of the opportunities presented to us."
Mr. Lilly is a Partner with Sostarich, Ross, Wright & Cecutti, llp, a
firm he joined 18 years ago. Prior to his current position, Mr. Lilly was a
Manager at Clarkson Gordon, now Ernst & Young, in Toronto. He has served as a
Director of the Boards of a number of publicly-listed companies, including,
Contact Diamond Corporation and Sudbury Capital Corp. Mr. Lilly received his
Chartered Accountant designation in 1986 and his Masters in Business
Administration from the University of Toronto in 1987.
About Bradmer Pharmaceuticals Inc. (www.bradmerpharma.com)
Bradmer Pharmaceuticals is a biopharmaceutical company focused on the
development and commercialization of new and innovative cancer therapies.
Bradmer's lead clinical candidate, Neuradiab, was developed at Duke University
Medical Center as a proprietary therapy for a particularly aggressive form of
brain cancer, glioblastoma multiforme. Prior to the Company's inception, over
US$60 million in grants and related support had driven research and
development of the licensed treatment, which has been delivered to over
200 patients with promising results in Phase I and Phase II clinical trials at
Duke University. Bradmer has initiated enrollment in a Phase III multi-center
clinical trial of the licensed treatment. Neuradiab has been granted Orphan
Drug Status by both the U.S. Food and Drug Administration and the European
Bradmer Pharmaceuticals Inc.'s common shares have not been registered
under the Securities Act of 1933, as amended (the "Securities Act") or any
state regulatory agency in the United States. The resale or transfer by a U.S.
investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to
the requirements of Rule 904 of Regulation S of the Securities Act or such
other applicable exemption thereunder, and other applicable state securities
Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current expectation
regarding future events. These forward-looking statements involve risks and
uncertainties, which may include but are not limited to, the receipt of all
regulatory approvals required to conduct the proposed clinical trial of
Neuradiab, changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact of
competitive products and pricing, new product development, uncertainties
related to the regulatory approval process and other risks detailed from time
to time in the Company's ongoing quarterly and annual reporting.
For further information:
For further information: Bradmer Pharmaceuticals Inc., Mr. Brian
Brohman, Chief Business Officer, Phone: (416) 361-6058 (Ext. 804), E-mail:
email@example.com, Internet: www.bradmerpharma.com; Investor
Relations, Ross Marshall, The Equicom Group Inc., Phone: (416) 815-0700 (Ext.
238), Fax: (416) 815-0080, E-mail: firstname.lastname@example.org